A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment Clinical Trial

Official title:

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03282513
• Other study ID #: AG120-C-012
• Status: Completed
• Phase: Phase 1
• First received: September 8, 2017
• Last updated: April 26, 2018
• Start date: September 26, 2017
• Est. completion date: March 31, 2018

Study information

• Verified date: April 2018
• Source: Agios Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study AG120-C-012 is a Phase 1, open-label, single-dose study designed to evaluate the PK, safety, and tolerability of a single 500 mg AG-120 (Ivosidenib) dose in subjects with mild or moderate hepatic impairment (HI) compared to subjects with normal hepatic function. The study will be conducted at 2 US centers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: March 31, 2018
• Est. primary completion date: March 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Key Inclusion Criteria:

All subjects:

• Body Mass Index BMI of 19 to 40 kg/m2 (inclusive).

• Willing and able to comply with all study restrictions and requirements.

• Non- smoker, or uses no more nicotine-containing product than the equivalent of smoking =10 cigarettes per day, as judged by the investigator.

• Female subjects must be non pregnant and non-lactating and either be post-menopausal, surgically sterile, practice total abstinence from sexual intercourse as the preferred lifestyle or agree to use an appropriate method of birth control consistently throughout the study, from screening until 90 days after study drug administration.

• Male subjects with a partner of child bearing potential must either be sterile, practice total abstinence from sexual intercourse as the preferred life style or agree to use an appropriate method of birth control consistently throughout the study, from screening until 90 days after study drug administration.

Subjects with hepatic impairment (Cohorts 1a, 2a)

• Diagnosis of chronic (=3 months prior to Screening) or stable (no acute episodes of illness within 2 months prior to Screening due to deterioration in hepatic function) hepatic insufficiency, with a Child-Pugh classification score in the mild or moderate range.

• Hepatic insufficiency may be of any etiology associated with an unambiguous medical history (such as evidence of portal hypertension).

• Other than hepatic insufficiency with features of cirrhosis, subjects are in good health based on medical history, physical exam, ECG, clinical laboratory tests, and Investigator's assessment.

Healthy matched subjects (Cohorts 1b, 2b)

• Have normal hepatic function and considered by the Investigator to be in good health, based on medical and surgical history review, physical exam, ECG, clinical laboratory tests, and Investigator's assessment.

Key Exclusion Criteria:

All subjects:

• Significant acute, new-onset illness (eg, flu, gastroenteritis) within 2 weeks prior to dosing.

• Positive test for drugs of abuse and/or positive alcohol test at Screening or prior to dosing.

• Medical history of clinically significant ECG abnormalities or a family history of prolonged QT interval syndromes.

• History of immunocompromise, including positivity for HIV, or active viral hepatitis B or C.

• Use of over the counter (OTC) medications, herbal supplements, grapefruit juice, Seville oranges, or vitamins 14 days prior to dosing.

• A recent (within 6 months prior to dosing) history of acute or chronic bronchospastic disease, including asthma and chronic obstructive pulmonary disease.

• Current or history of hepatic carcinoma, hepatorenal syndrome, portacaval shunt surgery, or pleural effusion. Malignancy, including leukemia and lymphoma, within the last 5 years.

• Any surgical or medical condition that might significantly alter the absorption, distribution, or excretion of AG-120.

• Treatment with strong cytochrome P450 (CYP)3A4 inhibitors or inducers within 14 days prior to AG 120 dosing or during the study.

Subjects with hepatic impairment (Cohorts 1a, 2a)

• Clinical evidence of moderate to severe ascites.

• Significant history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatologic, renal, hematologic, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurologic, or psychiatric disorder, as determined by the Investigator and/or Sponsor's medical monitor (MM) to be clinically significant (CS.)

• Any evidence of progressive liver disease (within the last 4 weeks prior to dosing)

• Severe or uncontrolled medical conditions within 4 weeks prior to AG-120 dosing, with the exception of illness related to HI.

Healthy Matched Subjects

• Clinical evidence of liver disease or liver injury

• History or presence of impaired renal function

• QTCF >450 (males) or >460 (females) or ECG findings deemed abnormal by the Investigator

• Use of any prescription medications within 30 days prior to dosing

Related Conditions & MeSH terms

• Hepatic Impairment
• Liver Diseases

Intervention

Drug:
• AG-120 (Ivosidenib)
Single 500 mg dose of AG-120 (Ivosidenib).

Locations

Country	Name	City	State
United States	DaVita Clinical Research- Colorado	Lakewood	Colorado
United States	DaVita Clinical Research- Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Agios Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum observed plasma concentration (Cmax)	AG-120 Cmax, derived from plasma concentration-time curves	Predose; 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 9hr, 12hr, 24hr, 48hr, 72hr, 120hr, 168hr, 240hr, 336hr, and 504hr post dose
Primary	Area under plasma concentration-time curve (AUC)	AG-120 AUC, derived from plasma concentration-time curves	Predose; 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 9hr, 12hr, 24hr, 48hr, 72hr, 120hr, 168hr, 240hr, 336hr, and 504hr post dose
Secondary	Adverse Events (AE) and treatment-related AE		From the time of study drug administration through the end of study (Day 29 or early termination)
Secondary	Plasma Protein Binding	Compare the plasma protein binding of AG-120 (Ivosidenib) in subjects with impaired HI with that in subjects with normal hepatic function.	Time Frame: Pre-dose, Day 1 and Day 2